ABSI vs. HARP, TCRX, STRO, ADAP, TNYA, NVEE, STER, TASK, PHR, and PSFE
Should you be buying Absci stock or one of its competitors? The main competitors of Absci include Harpoon Therapeutics (HARP), TScan Therapeutics (TCRX), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Tenaya Therapeutics (TNYA), NV5 Global (NVEE), Sterling Check (STER), TaskUs (TASK), Phreesia (PHR), and Paysafe (PSFE).
Harpoon Therapeutics (NASDAQ:HARP) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
Harpoon Therapeutics currently has a consensus target price of $27.25, suggesting a potential upside of 18.43%. Absci has a consensus target price of $8.40, suggesting a potential upside of 87.50%. Given Harpoon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Absci is more favorable than Harpoon Therapeutics.
74.0% of Harpoon Therapeutics shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 17.0% of Harpoon Therapeutics shares are owned by insiders. Comparatively, 9.8% of Absci shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Harpoon Therapeutics has a net margin of -81.68% compared to Harpoon Therapeutics' net margin of -2,042.01%. Harpoon Therapeutics' return on equity of -44.60% beat Absci's return on equity.
In the previous week, Absci had 3 more articles in the media than Harpoon Therapeutics. MarketBeat recorded 3 mentions for Absci and 0 mentions for Harpoon Therapeutics. Absci's average media sentiment score of 0.53 beat Harpoon Therapeutics' score of 0.49 indicating that Harpoon Therapeutics is being referred to more favorably in the media.
Harpoon Therapeutics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Harpoon Therapeutics received 70 more outperform votes than Absci when rated by MarketBeat users. Likewise, 59.12% of users gave Harpoon Therapeutics an outperform vote while only 55.81% of users gave Absci an outperform vote.
Harpoon Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.
Summary
Harpoon Therapeutics and Absci tied by winning 9 of the 18 factors compared between the two stocks.
Get Absci News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
